SCHEMBL22980163

SCHEMBL22980163

NNC(=O)c1cc(F)ccc1OC(F)(F)F

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SCN8A Q9UQD0 8/20 0.48
SCN10A Q9Y5Y9 8/20 0.48
EPHX2 P34913 1/20 0.44
KCNK3 O14649 3/20 0.43
KCNK9 Q9NPC2 3/20 0.43
F2R P25116 1/20 0.41
CTSD P07339 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
P2RX1 P51575 1/20 0.40
TMPRSS4 Q9NRS4 1/20 0.40
PYGL P06737 1/20 0.40
PTGER4 P35408 1/20 0.40
PTGER2 P43116 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29646420 1.00 SCN8A (0.48) SCN8ASCN10AEPHX2KCNK3KCNK9
SCHEMBL22979036 0.88 CTSD (0.45) EPHX2KCNK3KCNK9F2RCTSD
SCHEMBL29646468 0.83 ALDH1A1 (0.57) KDM4EKMT2AP2RX1TMPRSS4
SCHEMBL12874087 0.83 OGG1 (0.42) EPHX2KCNK3KCNK9KDM4EGAA
SCHEMBL22980173 0.83 ALDH1A1 (0.57) KDM4EKMT2AP2RX1TMPRSS4
SCHEMBL29646357 0.83 OGG1 (0.42) EPHX2KCNK3KCNK9KDM4EGAA
SCHEMBL23753927 0.82 EPHX2 (0.44) SCN8ASCN10AEPHX2KCNK3KCNK9
SCHEMBL29846944 0.82 EPHX2 (0.44) SCN8ASCN10AEPHX2KCNK3KCNK9
SCHEMBL376957 0.82 CTSD (0.62) KCNK3KCNK9F2RCTSDGAA
SCHEMBL29646406 0.82 CTSD (0.62) KCNK3KCNK9F2RCTSDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 SCN8A 4058/4885SCN10A 4298/4885EPHX2 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.